Drug intelligence / Profile preview

anti-murine CD62P

Development stage
Preclinical
Lead developer
Novartis
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal
01

Overview

Anti-murine CD62P refers to monoclonal antibodies, such as the clone RB40.34, that specifically target and inhibit murine P-selectin (CD62P). P-selectin is a cell adhesion molecule expressed on the surface of activated endothelial cells and platelets, playing a critical role in the recruitment of leukocytes to sites of inflammation and the formation of heterocellular aggregates. In preclinical models of sickle cell disease (SCD), inhibition of CD62P helps reduce vaso-occlusive events and organ damage by preventing the adhesion of sickle erythrocytes and leukocytes to the vascular endothelium. This research-grade antibody is often used as a surrogate for clinical P-selectin inhibitors like crizanlizumab to study the pathophysiology of SCD and other inflammatory conditions in mice.

Other names
anti-P-selectin antibodyanti-CD62P antibodyanti-CD-62P antibodyanti-CD 62P antibodyRB40.34 IgG1RB-40.34 IgG1RB 40.34 IgG1
02

Targets

SELP (P-selectin)

Beyond the preview

Go deeper on anti-murine CD62P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-murine CD62P.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call